Diabetes mellitus is a serious disease that arguably has reached global epidemic proportions. In their paper, Denise F. Messer, Claudia De Oliveira, Xiaoqiang Xue, Rick Turner and Erica Caveney of Quintiles scrutinisehow predictive analytics can facilitate more efficient study designs in development programmes for new antidiabetic drugs for type 2 diabetes mellitus (T2DM), with a brief recap of the essentials of the FDA and EMA guidelines and an account of how the drug development landscape has changed within the last decade or so.
https://international-pharma.com/wp-content/uploads/2014/10/Improving.pdf